{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:23:08Z","timestamp":1793082188609,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:00:00Z","timestamp":1707609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009519","name":"Ottawa Hospital Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009519","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omton.2024.200775","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T12:33:41Z","timestamp":1707827621000},"page":"200775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-7864","authenticated-orcid":false,"given":"Scott","family":"McComb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Arbabi-Ghahroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Faulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunle","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marcil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hussack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanand M.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"van Faassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Maclean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Gurnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gadoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jezierski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jez","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Pon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Sigrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risini D.","family":"Weeratna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200775_bib1","series-title":"CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions","first-page":"e246","author":"Gill","year":"2021"},{"key":"10.1016\/j.omton.2024.200775_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200775_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T\u00a0cells: Recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2024.200775_bib5","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200775_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200775_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 41BB co-stimulated CD22 CAR T\u00a0cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200775_bib8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcyt.2022.05.001","article-title":"CD20-specific chimeric antigen receptor-expressing T\u00a0cells as salvage therapy in rituximab-refractory\/relapsed B-cell non-Hodgkin lymphoma","volume":"24","author":"Cheng","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2024.200775_bib9","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2021.39.15_suppl.2508","article-title":"Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy","volume":"39","author":"Liang","year":"2021","journal-title":"J.\u00a0Clin. Orthod."},{"key":"10.1016\/j.omton.2024.200775_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features and therapeutic potential","volume":"45","author":"K\u00f6nning","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.omton.2024.200775_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies","volume":"414","author":"Arbabi Ghahroudi","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omton.2024.200775_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of Nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"10.1016\/j.omton.2024.200775_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","article-title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"39","author":"Martin","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.omton.2024.200775_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S288546","article-title":"Targeting CD22 for the Treatment of B-Cell Malignancies","volume":"10","author":"Shah","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.omton.2024.200775_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-1-59745-554-1_17","article-title":"Production of chimeric heavy-chain antibodies","volume":"525","author":"Zhang","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2024.200775_bib17","article-title":"Single-domain antibodies and their utility","volume":"103","author":"Baral","year":"2013","journal-title":"Curr. Protoc. Im."},{"key":"10.1016\/j.omton.2024.200775_bib18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bbagen.2015.03.009","article-title":"Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells","volume":"1850","author":"Rossotti","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omton.2024.200775_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omtm.2020.01.012","article-title":"A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells","volume":"16","author":"Bloemberg","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200775_bib20","series-title":"M971 chimeric antigen receptors","author":"Orentas","year":"2020"},{"key":"10.1016\/j.omton.2024.200775_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864868","article-title":"Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation","volume":"13","author":"McComb","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074740","article-title":"CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies","volume":"13","author":"Kekre","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41598-018-19522-8","article-title":"A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis","volume":"8","author":"Ribecco-Lutkiewicz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2024.200775_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib26","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","article-title":"Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer\u2019s disease","volume":"11","author":"Olah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200775_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-019-1088-4","article-title":"CD22 blockade restores homeostatic microglial phagocytosis in aging brains","volume":"568","author":"Pluvinage","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200775_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omton.2024.200775_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.omton.2024.200775_bib30","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T\u00a0cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200775_bib31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T\u00a0cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200775_bib32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22\u2013chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200775_bib33","article-title":"Efficient elimination of primary B-ALL cells in\u00a0vitro and in\u00a0vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope","volume":"8","author":"Velasco-Hernandez","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200775_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00713","article-title":"High-Affinity Ligands Can Trigger T Cell Receptor Signaling Without CD45 Segregation","volume":"9","author":"Al-Aghbar","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101538","article-title":"Nanobody-based anti-CD22-chimeric antigen receptor T\u00a0cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01519","article-title":"The CD28 Transmembrane Domain Contains an Essential Dimerization Motif","volume":"11","author":"Leddon","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200775_bib39","first-page":"111","article-title":"CD28 co-stimulation in T-cell homeostasis: a recent perspective","volume":"4","author":"Beyersdorf","year":"2015","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.omton.2024.200775_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.954345","article-title":"Efficacy and safety of CD22-specific and CD19\/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200775_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00251-018-01102-9","article-title":"Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct","volume":"71","author":"Henry","year":"2019","journal-title":"Immunogenetics"},{"key":"10.1016\/j.omton.2024.200775_bib42","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1074\/jbc.M110.198754","article-title":"Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain","volume":"286","author":"Hussack","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omton.2024.200775_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10616-010-9252-6","article-title":"PCR-based detection and eradication of mycoplasmal infections from various mammalian cell lines: a local experience","volume":"61","author":"Molla Kazemiha","year":"2009","journal-title":"Cytotechnology"},{"key":"10.1016\/j.omton.2024.200775_bib44","series-title":"Anti-cd22 single domain antibodies and therapeutic constructs","author":"McComb","year":"2023"},{"key":"10.1016\/j.omton.2024.200775_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.omtm.2022.05.006","article-title":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","volume":"26","author":"Rive","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:13Z","timestamp":1778938633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2950329924000171"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200775","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024","name":"copyright","label":"Copyright"}],"article-number":"200775"}}